⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12023026 | 0.84 | TSHR (0.40) | — | |
| SCHEMBL17613682 | 0.82 | — | — | |
| SCHEMBL17613643 | 0.82 | — | — | |
| SCHEMBL14566357 | 0.77 | HDAC3 (0.35) | — | |
| SCHEMBL18179179 | 0.77 | THRB (0.33) | — | |
| SCHEMBL17613623 | 0.75 | — | — | |
| SCHEMBL12022580 | 0.74 | — | — | |
| SCHEMBL17599662 | 0.73 | TDP1 (0.32) | — | |
| SCHEMBL12022443 | 0.73 | — | — | |
| SCHEMBL12023181 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190144488-A1 | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2019-05-16 | — | — | US | claimed |
| EP-3442983-A1 | TRITYL-MONO-Ga1NAc COMPOUNDS AND THEIR USE | H. Hoffnabb-La Roche Ag (CH) | 2019-02-20 | — | — | EP | claimed |
| US-20170327524-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | HOFFMANN-LA ROCHE INC. | 2017-11-16 | — | — | US | claimed |
| WO-2017178656-A1 | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2017-10-19 | — | — | WO | claimed |
| EP-3204397-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | F. Hoffmann-La Roche AG (CH) | 2017-08-16 | — | — | EP | claimed |
| WO-2016055601-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-14 | — | — | WO | claimed |
| US-20230009757-A1 | COMBINATION THERAPY FOR C3 INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-11338013-B2 | Combination therapy for C3 inhibition | APELLIS PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11248019-B2 | Trityl-mono-GalNAc compounds and their use | HOFFMANN-LA ROCHE INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210017214-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | HOFFMANN LA ROCHE (US) | 2021-01-21 | — | — | US | disclosed |
| US-20200282012-A1 | COMBINATION THERAPY FOR C3 INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| EP-3526328-A1 | COMBINATION THERAPY FOR C3 INHIBITION | Apellis Pharmaceuticals, Inc. (US) | 2019-08-21 | — | — | EP | disclosed |
| US-20190144488-A1 | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2019-05-16 | — | — | US | disclosed |
| EP-3067359-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | Petersen, Scott G. (US) | 2016-09-14 | — | — | EP | disclosed |
| WO-2016055601-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-14 | — | — | WO | disclosed |
| EP-2346883-B1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | PETERSEN SCOTT G (US) | 2016-03-23 | — | — | EP | disclosed |
| US-20140329775-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | PETERSEN SCOTT G (US) | 2014-11-06 | — | — | US | disclosed |
| US-20110294869-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | TRAVERSA THERAPEUTICS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| EP-2346883-A2 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | Traversa Therapeutics, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010039543-A2 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | TRAVERSA THERAPEUTICS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |